Mucoadhesive micelles for delivery of drugs to the lung for the prophylactic treatment of COVID-19

COVID-19导致的死亡人数飙升以及当前经济形势的不可持续性，使全球迫切需要创新的解决方案，以在预期的经济重启时保护公众。 该项目将专注于开发一种用于COVID-19暴露后预防的鼻喷雾剂配方，这将有助于控制感染人数，从而加快公众安全恢复正常生活，并有助于在预期的第二波疫情中进行控制。该提案提供了一种创新的、直接的和可扩展的预防方法，该方法可以通过将抗病毒药物与专有和专利的粘膜粘附胶束相结合来自我给药，以提供针对感染的长期保护作用。我们将专注于含有羟氯喹（HCQ）或新型血管生成素-Tie 2抑制剂的鼻喷雾剂的配方，该药物为我们的合作伙伴Mannin Research Inc.所有。每种药物将被纳入专利粘膜粘附胶束输送系统从Sheardown实验室。这些制剂将作为预防剂，防止引起COVID-19的SARS-CoV-2病毒进入呼吸道，或将其影响和严重程度降至最低。然后，它们将与Mannin合作开发用于临床。

The soaring death tolls from COVID-19 and the non-sustainability of the current economic situation pose an urgent worldwide need for an innovative solution to protect the public upon the anticipated restart of the economy. This project will focus on the development of a nasal spray formulation for post-exposure prophylaxis against COVID-19 which will help control the number of infections and, in turn, hasten the safe return of the public to normal life as well as being useful for control in the anticipated second wave. This proposal offers an innovative, straightforward and scalable prophylactic approach that can be self-administered by combining anti-viral drugs with proprietary and patented mucoadhesive micelles to provide a prolonged protective effect against infection. We will focus on the formulation of a nasal spray containing either hydroxychloroquine (HCQ) or a novel Angiopoietin-Tie2 inhibitor, which is proprietary to our partner Mannin Research Inc. Each drug will be incorporated into the patented mucoadhesive micelle delivery system from the Sheardown lab. These formulations will act as a prophylactic, either preventing entry of SARS-CoV-2, the virus responsible for COVID-19, into the respiratory tract or minimizing its impact and severity. They will then be developed for clinical use in partnership with Mannin.